AdaptivCRT success in Heart Failure

Medtronic, Inc.announced clinical trial results showing that Heart Failure patients treated with its exclusive AdaptivCRT feature (in the Medtronic Viva portfolio of CRT-D devices) experienced a nearly 50 per-cent reduction in atrial fibrillation (AF) risk. Pioneered by Medtronic, the AdaptivCRT technology is a feature on certain cardiac resynchronization therapy-defibrillators (CRT-Ds) that continually adjusts therapy to a patient's natural heart rhythms and minimizes the amount of unnecessary right ventricular (RV) pacing. The results were presented as a late breaking clinical trial at the Heart Failure Society of America's 17th Annual Scientific Meeting.

Because the AdaptivCRT technology utilizes the heart's natural rhythm to continuously adjust therapy, patients in the study who received AdaptivCRT experienced a 34 per-cent reduction in right ventricular pacing compared to conventional CRT. Long-term study outcomes presented show that patients receiving the AdaptivCRT technology were at a 46 per-cent lower risk of spending 48 consecutive hours or more in AF compared to conventional CRT patients. Earlier research showed that the use of the AdaptivCRT feature improves Heart Failure patients' response rate to cardiac resynchronization therapy, resulting in a projected 21 per-cent reduction in overall Heart Failure hospitalizations within the first year after implant, as compared to historical CRT trials.This presentation also reinforced the safety and effectiveness of the AdaptivCRT feature.